Diabetes and Bone Health: The Unseen Complications

Diabetes mellitus affects over 537 million adults globally, and while its impact on blood glucose, cardiovascular function, and kidney health is well documented, its effects on the skeletal system are often overlooked. Both type 1 and type 2 diabetes are associated with a significantly increased risk of fractures, particularly at the hip, spine, and wrist. A meta-analysis of prospective studies found that individuals with type 2 diabetes have a 40–70% higher risk of hip fracture compared to non-diabetic controls, even after adjusting for bone mineral density (BMD). This elevated fracture risk persists despite normal or even BMD, suggesting that diabetes degrades bone quality beyond simple density loss. Factors such as chronic hyperglycemia, oxidative stress, accumulation of advanced glycation end-products (AGEs), impaired osteoblast function, and altered mineral metabolism all contribute to a weakened bone matrix. In this context, the role of trace minerals like manganese has gained increasing attention. Manganese is a cofactor for several enzymes essential to bone formation and mineralization, and recent evidence indicates that supplementation may offset some of the skeletal damage caused by diabetes.

Manganese: A Vital Cofactor in Bone Metabolism

Manganese (Mn) is an essential trace element that activates a wide array of enzymes. While the total body content of manganese is only around 10–20 mg, it is concentrated in the liver, kidneys, pancreas, and bones. In bone tissue, manganese is particularly critical for:

  • Glycosyltransferases – These enzymes catalyze the synthesis of glycosaminoglycans (e.g., chondroitin sulfate, hyaluronic acid), key components of the cartilage and bone extracellular matrix. Without adequate manganese, proteoglycan synthesis is impaired, compromising the structural integrity of bone.
  • Xanthine oxidase – Involved in collagen cross-linking, which gives bone its tensile strength and resistance to fracture. Manganese deficiency leads to disorganized collagen fibrils and weaker bone.
  • Superoxide dismutase (Mn-SOD) – The mitochondrial form of this antioxidant enzyme protects osteoblasts and osteocytes from oxidative damage. Since diabetes elevates reactive oxygen species (ROS) production, Mn-SOD activity becomes especially important.
  • Pyruvate carboxylase – Participates in gluconeogenesis and influences energy metabolism in bone cells, indirectly supporting the ATP requirements of bone remodeling.
  • Phosphoenolpyruvate carboxykinase (PEPCK) – Another gluconeogenic enzyme that may affect osteoblast function via metabolic pathways.

Manganese also regulates osteoblast differentiation and activity. In vitro studies show that manganese deprivation reduces alkaline phosphatase (ALP) activity, a marker of bone formation, and impairs mineralization. Conversely, adequate manganese levels promote the deposition of hydroxyapatite crystals into the collagen matrix, strengthening the skeleton. A study using osteoblast-like MG63 cells demonstrated that manganese supplementation increased ALP activity by 30% and enhanced mineral nodule formation, highlighting its direct role in bone building.

How Diabetes Disrupts Manganese Homeostasis

Diabetes alters the metabolism of several minerals, including zinc, copper, and manganese. Hyperglycemia increases urinary excretion of manganese, leading to lower circulating levels in diabetic individuals. One study reported that serum manganese was 15–20% lower in type 2 diabetic patients compared to healthy controls, with an inverse correlation to HbA1c. Additionally, insulin resistance may impair cellular uptake of manganese via the insulin-sensitive metal transporter DMT1 (divalent metal transporter 1) and the zinc transporter ZIP8, further reducing its availability to bone-forming cells. Chronic inflammation, a hallmark of diabetes, also alters the expression of transporters in the gut and kidneys: pro-inflammatory cytokines like TNF-α downregulate DMT1 expression in the duodenum, potentially reducing absorption. These disruptions create a scenario where even a diet adequate in manganese may fail to deliver sufficient amounts to target tissues, especially bone.

Mechanisms of Diabetes-Induced Skeletal Deterioration

To appreciate how manganese supplementation might help, it is essential to understand the multiple pathways through which diabetes damages bone.

Hyperglycemia and Osteoblast Dysfunction

High glucose levels directly suppress osteoblast activity. Glucose competes with ascorbic acid (vitamin C) for uptake into osteoblasts via GLUT transporters, reducing collagen synthesis. Moreover, hyperglycemia upregulates the expression of sclerostin, a Wnt signaling inhibitor that decreases bone formation. Osteoblasts also become more susceptible to apoptosis under high-glucose conditions due to increased intracellular ROS and activation of caspases. A study showed that cyclic stretch, which normally stimulates osteoblast proliferation, fails to do so in a high-glucose environment, indicating that hyperglycemia blunts the mechanical signaling that maintains bone mass.

Advanced Glycation End-Products (AGEs)

Chronic hyperglycemia leads to the non-enzymatic glycation of proteins in bone, such as collagen type I and osteocalcin. These AGEs form cross-links that stiffen the collagen matrix, making bone more brittle and less able to absorb energy before fracture. AGEs also bind to the receptor RAGE on osteoblasts and osteoclasts, promoting inflammation and oxidative stress. RAGE activation suppresses osteoblast differentiation while stimulating osteoclastogenesis, tilting the bone remodeling balance toward net loss. Studies have shown that serum AGE levels correlate inversely with bone strength (measured by microindentation) in diabetic patients, independent of BMD.

Oxidative Stress and Inflammation

Diabetes generates an excess of reactive oxygen species (ROS) due to mitochondrial dysfunction, glucose autoxidation, activation of the polyol pathway, and uncoupling of endothelial nitric oxide synthase. ROS directly damage bone cells and matrix components. Inflammatory cytokines like TNF-α and IL-6, elevated in diabetes, stimulate osteoclastogenesis via RANKL signaling while inhibiting osteoblast differentiation. Manganese, as an essential component of Mn-SOD, plays a direct role in neutralizing superoxide radicals in the mitochondria. By bolstering the antioxidant defenses of bone cells, manganese may help curb the oxidative damage that accelerates bone loss. Indeed, diabetic patients with higher Mn-SOD activity have been shown to have better bone quality.

Evidence for Manganese Supplementation in Diabetic Bone Disease

Research into manganese supplementation for diabetic skeletal health is still evolving, but existing studies provide a strong rationale for its use.

Animal Studies

In streptozotocin-induced diabetic rats, oral manganese supplementation improved bone mineral density (BMD), increased bone strength (measured by maximum load and stiffness), and normalized alkaline phosphatase levels. Histological examination showed enhanced trabecular bone volume and reduced osteoclast surface. A 2020 study fed diabetic rats a diet supplemented with 45 mg/kg manganese for eight weeks. Compared to diabetic controls, supplemented rats had significantly higher vertebral bone mineral content (BMC, +18%) and reduced urinary excretion of deoxypyridinoline (a marker of bone resorption, –25%). The supplemented group also showed lower oxidative stress markers in bone tissue, suggesting a direct antioxidant effect.

Human Observational Data

In cross-sectional studies, serum manganese levels are often lower in diabetic patients with osteoporosis than in those with normal bone density. A study of 1,200 postmenopausal women with type 2 diabetes found that those in the highest tertile of dietary manganese intake had a 40% lower prevalence of osteopenia and osteoporosis compared to those in the lowest tertile, after adjusting for age, BMI, diabetes duration, and calcium intake. Another analysis of NHANES data revealed that diabetic individuals with serum manganese in the lowest quartile had a 2.1-fold higher odds of hip fracture over a 10-year follow-up. While correlation does not prove causation, these data suggest a protective association that merits further investigation.

Clinical Trials

Randomized controlled trials examining isolated manganese supplementation in diabetic populations are scarce. However, several trials using multinutrient formulas containing manganese (alongside zinc, copper, and vitamin D) have reported improvements in bone turnover markers and BMD in diabetic subjects. For instance, a 12-week supplementation with a trace mineral complex including 5 mg/day manganese led to reduced serum C-terminal telopeptide (CTX-1, a resorption marker) by 12% and increased osteocalcin (a formation marker) by 8% in type 2 diabetic patients. A more recent 24-week trial in 80 diabetic postmenopausal women compared a daily supplement delivering 10 mg manganese, 15 mg zinc, 2 mg copper, and 800 IU vitamin D against a vitamin D–only control. The combination group showed a significant increase in lumbar spine BMD (+3.1%) and a decrease in the RANKL/OPG ratio, indicating reduced osteoclast activity. These results warrant further investigation into manganese as a standalone intervention, as well as its synergistic effects with other bone-supportive nutrients.

Dietary Sources and Bioavailability of Manganese

Manganese is present in a variety of foods, but its absorption can be significantly affected by diabetes medications and other dietary factors. Understanding these nuances is critical for optimizing intake.

Rich Food Sources

The following foods provide substantial amounts of manganese (values per 100 g cooked, unless noted; source: USDA FoodData Central):

  • Pine nuts: ~8.8 mg
  • Hazelnuts: ~6.2 mg
  • Pecans: ~4.5 mg
  • Pumpkin seeds: ~4.5 mg (roasted)
  • Whole wheat flour: ~4.0 mg (raw)
  • Brown rice: ~1.1 mg (cooked)
  • Spinach: ~0.9 mg (cooked, boiled)
  • Pineapple: ~0.9 mg (raw)
  • Black tea: ~0.5 mg per cup (steeped, variable)

Factors Affecting Absorption

Manganese absorption in the gut is competed for by iron, calcium, and zinc due to shared transporters (DMT1 and ZIP14). Diabetic patients who take calcium or iron supplements may need to space them apart from manganese-rich foods or supplements by at least 2 hours. High-fiber diets (phytates in whole grains, legumes) can reduce manganese absorption moderately because phytates bind divalent cations. Conversely, vitamin C and the presence of organic acids (citric acid, malic acid) enhance absorption by keeping manganese in a soluble, reduced form. Metformin, a first-line diabetes drug, has been shown to reduce the absorption of several minerals, including manganese, by altering gut pH and downregulating DMT1 expression. Therefore, diabetic patients on metformin may be at increased risk of suboptimal manganese status and could benefit from periodic serum manganese assessment.

In the United States, the adequate intake (AI) for manganese in adults is 2.3 mg/day for men and 1.8 mg/day for women. The tolerable upper intake level (UL) is 11 mg/day from supplements and foods combined — well above typical intakes. Common manganese supplements provide 5–10 mg per dose, often as manganese gluconate, citrate, or sulfate. Toxicity from oral supplementation is rare when consuming less than 10 mg/day, but chronic intake above the UL, especially in the presence of impaired hepatic or renal clearance, can cause neurological symptoms resembling Parkinsonism (manganism) due to manganese accumulation in the basal ganglia. Because diabetes may compromise liver and kidney function, patients with diabetic nephropathy or steatohepatitis should use manganese supplements with caution and under medical supervision. A simple serum manganese test can help determine baseline status and guide dosing. If serum manganese is already in the normal range (4.7–18.3 ng/mL), supplementation may not be necessary, and focused dietary intake may suffice.

Practical Recommendations for Diabetic Patients

Based on current evidence, the following strategies may support skeletal health in diabetes through optimized manganese status:

  1. Prioritize dietary sources first. Incorporate manganese-rich foods like nuts, seeds, leafy greens, and whole grains into daily meals. This approach provides the mineral along with fiber, healthy fats, and other bone-supportive nutrients (magnesium, vitamin K, copper). For example, a handful of almonds (30 g) provides about 1.2 mg manganese, while a cup of cooked oatmeal offers 1.5 mg.
  2. Manage supplement timing and interactions. If you take metformin, iron supplements, or calcium, ensure adequate spacing (at least 2 hours apart) from manganese-rich meals or supplements. Manganese is best absorbed on an empty stomach, but if stomach upset occurs, take it with a low-inhibitor meal (e.g., fruits, non-citrus vegetables).
  3. Consider a combined approach. Manganese works synergistically with zinc, copper, and vitamin D. A comprehensive bone support formula may be more effective than manganese alone, as these nutrients share metabolic pathways. For instance, zinc activates osteoblast differentiation, copper is required for collagen cross-linking, and vitamin D enhances calcium absorption and osteocalcin synthesis.
  4. Avoid exceeding 10 mg/day without medical supervision. Higher doses are not proven to be more beneficial for bone health and carry risks of neurological accumulation. A standard 5–10 mg daily augmentation, combined with dietary intake, is likely safe and adequate for correcting deficiency.
  5. Pair with metabolic control. Manganese supplementation should be part of a broader strategy to optimize blood glucose, as hyperglycemia drives both manganese wasting and bone degradation. Better glycemic control reduces the demand for antioxidants and may improve manganese utilization. Aiming for an HbA1c below 7% (53 mmol/mol) can synergize with any bone-supportive intervention.
  6. Monitor bone health regularly. Diabetic patients should discuss bone density testing (DXA scan) and fracture risk assessment with their healthcare provider, especially if they have a history of fragility fractures, long diabetes duration, or neuropathy. Adding a serum manganese test to annual labs can help individualize supplementation.

Conclusion: Manganese as a Targeted Support for Diabetic Skeletal Health

Diabetes imposes a multifaceted burden on the skeleton, from impaired bone formation to increased brittleness and fracture susceptibility. Manganese deficiency is common in diabetic patients, driven by urinary losses, malabsorption, and drug interactions, and this deficiency likely exacerbates bone deterioration. Supplementation with physiological doses of manganese can correct this deficit, support the activity of antioxidant enzymes like Mn-SOD, enhance collagen synthesis through glycosyltransferases, and improve bone mineralization. While more large-scale clinical trials are needed to establish definitive efficacy and optimal dosing, the existing biochemical, animal, and early clinical evidence is compelling. For patients with diabetes who are concerned about bone health, a targeted approach that includes adequate manganese intake — alongside standard vitamin D, calcium, and glycemic management — represents a low-risk, potentially high-reward strategy. As with any nutritional intervention, individualization based on blood levels, kidney function, and medication use is key. Partner with a knowledgeable healthcare provider to determine if manganese supplementation is right for you, and take a proactive step toward preserving skeletal integrity in the face of diabetes.

For further reading on manganese and bone health, refer to the NIH Office of Dietary Supplements – Manganese Fact Sheet and a comprehensive review on trace elements in diabetes and bone. Additionally, Diabetes Care provides an overview of diabetes and bone disease. For more on oxidative stress and antioxidant enzymes in diabetic bone, see this study on Mn-SOD activity in diabetic patients.